HIMS vs NVO Stock Comparison: AI Score, Valuation, Performance and Upside
Hims & Hers is typically evaluated as a fast-growing consumer health platform whose fortunes are increasingly tied to its distribution relationship with GLP-1 manufacturers, while Novo Nordisk is judged as the underlying drug innovator and manufacturer defending its franchise against rivals and new distribution channels. The two now sit on opposite ends of the same supply chain after settling their 2026 legal dispute and striking a partnership. The choice between them depends on whether an investor wants exposure to branded drug economics or to the consumer-facing distribution layer.
Novo Nordisk suits investors seeking established, profitable exposure to GLP-1 drug economics at a pharma valuation, while Hims & Hers is a higher-beta bet on telehealth distribution scaling faster than its subscriber-acquisition costs.
NVO holds the edge across 3 of 5 key metrics in this comparison. NVO leads on both 1-year return (-15.70%) and forward P/E quality (2.06x vs 26.55x for HIMS), a relatively favorable combination of momentum and valuation. On fundamentals, HIMS is growing revenue faster (38.20%), while NVO maintains the higher operating margin (42.54%) — a classic growth-versus-profitability split. Analyst consensus implies similar upside for both: +5.58% for HIMS and +4.16% for NVO.
- Want exposure to consumer telehealth growth
- Believe direct-to-consumer distribution will keep winning share in weight loss
- Can tolerate regulatory and legal headline risk
- Prefer a smaller-cap, higher-volatility healthcare name
- Want established, profitable exposure to the GLP-1 market
- Prefer a diversified pharmaceutical company over a single-category platform
- Are comfortable with European pharma valuation and reporting conventions
- Value dividend income alongside growth
| Metric | HIMS | NVO |
|---|---|---|
| AI score | 42.9 | 38.0 |
| AI rank | #822 | #1283 |
| Latest close | $29.58 | $45.33 |
| 1M return | +6.52% | -2.49% |
| 6M return | +103.72% | +27.08% |
| 1Y return | -30.15% | -15.70% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | HIMS | NVO |
|---|---|---|
| 1Y ago | $7.12K (-28.8%) started 2025-09-02 | $8.86K (-11.4%) started 2025-09-02 |
| 5Y ago | $37.54K (+275.4%) started 2021-08-31 | $11.46K (+14.6%) started 2021-08-31 |
| 10Y ago | $30.18K (+201.8%) started 2019-09-13 | $31.77K (+217.7%) started 2016-08-31 |
Hypothetical — past performance does not guarantee future results.
| Metric | HIMS | NVO |
|---|---|---|
| Market cap | $6.9B | $200.41B |
| Trailing P/E | N/A | 11.08 |
| Forward P/E | 26.55 | 2.06 |
| Price/Sales | 2.68 | 0.61 |
| EV/Revenue | 2.88 | 0.90 |
| Analyst target | $31.23 | $47.21 |
| Target upside | +5.58% | +4.16% |
| Metric | HIMS | NVO |
|---|---|---|
| Revenue growth | 38.20% | 2.10% |
| Earnings growth | N/A | -20.60% |
| EPS growth | N/A | -20.60% |
| FCF margin | +32.95% | +11.44% |
| Operating margin | -12.75% | 42.54% |
| Profit margin | -5.51% | 35.35% |
| ROIC proxy | -32.03% | 59.81% |
| Return on equity | -32.03% | 59.81% |
| Dividend yield | 0.00% | 3.94% |
| Beta | 2.42 | 0.35 |
| Debt/equity | 477.13 | 63.33 |
| Current ratio | 0.93 | 0.87 |
| Quick ratio | 0.82 | 0.64 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | HIMS | NVO |
|---|---|---|---|
| 1Y | Growth | -28.77% | -15.59% |
| CAGR | -28.92% | -15.67% | |
| Sharpe ratio | 0.04 | -0.24 | |
| Max drawdown | 76.86% | 43.67% | |
| Max daily drop | 16.03% | 16.43% | |
| Max wkly drop | 32.71% | 26.95% | |
| 5Y | Growth | +275.38% | +1.69% |
| CAGR | +30.29% | +0.34% | |
| Sharpe ratio | 0.68 | 0.09 | |
| Max drawdown | 78.88% | 74.70% | |
| Max daily drop | 34.63% | 21.83% | |
| Max wkly drop | 39.06% | 33.45% | |
| 10Y | Growth | +201.84% | +145.10% |
| CAGR | +17.19% | +9.38% | |
| Sharpe ratio | 0.53 | 0.30 | |
| Max drawdown | 87.29% | 74.70% | |
| Max daily drop | 34.63% | 21.83% | |
| Max wkly drop | 39.06% | 33.45% |
| Category | HIMS | NVO |
|---|---|---|
| Company | Hims & Hers Health, Inc. | Novo Nordisk A/S |
| Sector | Healthcare / Telehealth | Healthcare / Pharmaceuticals |
| Industry | N/A | N/A |
| Core business | Hims & Hers operates a direct-to-consumer telehealth platform offering subscriptions for weight loss, sexual health, dermatology, and mental health treatments. | Novo Nordisk is a Danish pharmaceutical company and maker of semaglutide-based drugs Ozempic and Wegovy, alongside a broader diabetes and rare-disease portfolio. |
| Investor focus | Investors watch subscriber growth, weight-loss category revenue, and the durability of its restructured distribution partnership with Novo Nordisk for branded GLP-1 drugs. | Investors focus on GLP-1 market share retention against Eli Lilly, manufacturing capacity expansion, and pricing pressure in the U.S. obesity-drug market. |
- Fast-growing subscriber base across a multi-category telehealth platform
- Now an authorized channel for branded Wegovy and Ozempic after settling with Novo Nordisk
- Asset-light model with high gross margins and strong direct-to-consumer marketing reach
- Global leadership in GLP-1 diabetes and obesity treatments
- Large manufacturing capacity expansion underway to meet Wegovy demand
- Diversified pipeline beyond GLP-1, including rare disease and cardiovascular drugs
- Regulatory scrutiny over past compounded-drug marketing and prior legal disputes with Novo Nordisk
- Reliance on continued access to GLP-1 supply on favorable terms
- Rising customer acquisition costs and churn in an increasingly competitive telehealth market
- Intensifying competition from Eli Lilly's tirzepatide franchise
- Pricing pressure and channel disruption from compounded and telehealth-distributed alternatives
- Execution risk on manufacturing scale-up and the oral semaglutide rollout
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.